Willy

79 years old,

Retired construction worker

Read The Story

Avastin, approved nearly 15 years ago and reimbursed in Belgium for 10 years*, was the first-ever anti-angiogenic agent to offer a clinically meaningful survival benefit to 1st line metastatic colorectal cancer (mCRC) patients^1,2.

Today, more than 3 million patients worldwide have been treated with Avastin in multiple cancer types.³